U-M researchers open new leads in anti-HIV drug development, using a compound found in nature
A team of University of Michigan researchers has successfully modified a naturally occurring chemical compound in the lab, resulting in advanced lead compounds with anti-HIV activity.
Their results, published March 7 in the Journal of Medicinal Chemistry, offer a new path forward in the development of drugs that could potentially help cure—rather than treat—HIV.
Although effective treatments are available to manage HIV, a cure has remained elusive due to the virus's ability to hide from the immune system, lying dormant in reservoirs of infected cells.
"With most viruses, when people get infected, they get sick for a while and then the immune system kicks in and the virus is cleared," said Kathleen Collins, professor of microbiology and immunology at the U-M Medical School. "But with HIV, once a patient is infected, that virus will persist for their entire life—meaning they must remain on treatments indefinitely."
One key to HIV's ability to remain hidden in patients' cells is a protein that the virus makes, called Nef. This protein shuts down a system that the cell would normally use to alert the immune system to an infection, thus preventing the immune cells from recognizing and clearing the virus.
Collins and her lab have studied this protein for more than 15 years, investigating how it works and how it can be disabled. She and David Sherman, professor at the U-M Life Sciences Institute, previously discovered that a chemical found in nature can inhibit HIV Nef, allowing the immune system to find and eliminate virally infected cells: a compound called concanamycin A (CMA), which is produced by a soil-derived microorganism.
In its natural form, however, CMA presents several challenges as a potential therapeutic. The first challenge the team had to overcome was supply. While CMA is a naturally occurring compound, the original bacteria that produces it does so in quantities far too small to be useful for testing and modification in the lab.
Another major challenge with developing CMA as an anti-HIV drug is that Nef is not CMA's primary target.
"CMA's main job in human cells is to inhibit an enzyme called V-ATPase, which we absolutely do not want to block in this case," said Sherman, who is also a professor at the U-M College of Pharmacy, Medical School, and College of Literature, Science, and the Arts. "So, we needed to find a way to modify CMA's activity, widening the effective dosage gap between when it starts to inhibit the target we're aiming for—HIV Nef — without affecting V-ATPase, its typical cellular target."
With this latest research, the team has overcome both of these challenges. Using bioengineering, Sherman's team was able to develop a bacterial strain that increased CMA production 2,000-fold. Synthetic chemists in the lab then created more than 70 new variations of the compound, swapping out different chemical groups, to test for their potency against HIV Nef.
Collins' lab team ran the new compounds through a battery of tests to measure their toxicity to cells, as well as how they affected the activities of both HIV Nef and V-ATPase.
"Even though we know that CMA is extremely active against the HIV Nef protein, all drugs have side effects," said Collins, also a professor of internal medicine at the Medical School. "And so we wanted to ensure we've done everything we can to minimize the side effect profile of the drug before we consider putting it into an animal or human."
The team now has several CMA analogs that show high potency in blocking HIV Nef at very low dosage levels, without interrupting off-target effects or causing toxicity in human cells. They caution, however, that several important steps remain before the compounds would be ready for further testing in a clinical setting.
"We are really encouraged, though, because our groups have solved some very important problems," Sherman said. "We have engineered microorganisms to produce sustainable supplies of the natural product molecules and have really good chemical methods to make new analogs. And we have the methodologies in place to continue tracking the critical toxicity and potency parameters to further reduce off-target effects."
The research was supported by the National Institutes of Health.
Other study authors are: Morgan McCauley, Matthew Huston, Alanna Condren, Filipa Pereira, Joel Cline, Marianne Yaple-Maresh, Mark Painter, Gretchen Zimmerman, Andrew Robertson, Nolan Carney, Christopher Goodall and Valeri Terry of U-M and Rolf Müller of Hemholtz Institute for Pharmaceutical Research, Germany.
Study: Structure-activity relationships of natural and semisynthetic plecomacrolides suggest distinct pathways for HIV-1 immune evasion and vacuolar ATPase-dependent lysosomal acidification (DOI: 10.1021/acs.jmedchem.3c01574)
Written by Emily Kagey, U-M Life Sciences Institute
JOURNAL
Journal of Medicinal Chemistry
No comments:
Post a Comment